The estimated Net Worth of Aoife Brennan is at least $1.95 millió dollars as of 7 June 2023. Aoife Brennan owns over 4,733 units of Synlogic Inc stock worth over $38,567 and over the last 7 years he sold SYBX stock worth over $114,195. In addition, he makes $1,793,870 as President, Chief Executive Officer és Director at Synlogic Inc.
Sign up
Aoife Brennan SYBX stock SEC Form 4 insiders trading
Aoife has made over 3 trades of the Synlogic Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 4,733 units of SYBX stock worth $81,360 on 7 June 2023.
The largest trade he's ever made was selling 19,042 units of Synlogic Inc stock on 3 April 2023 worth over $11,044. On average, Aoife trades about 1,719 units every 23 days since 2018. As of 7 June 2023 he still owns at least 27,947 units of Synlogic Inc stock.
You can see the complete history of Aoife Brennan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Aoife Brennan biography
Dr. Aoife M. Brennan serves as President, Chief Executive Officer, Director of the Company. Dr. Brennan served as Chief Medical Officer of Private Synlogic and was responsible for the oversight and direction of its clinical development strategy and operations. From May 2011 to August 2016, Dr. Brennan was Vice President and Head of the Rare Disease Innovation Unit at Biogen, a biotechnology company, where she was responsible for research and development of the Biogen rare disease portfolio, which involved programs ranging from pre-clinical to commercial, including the approval of ALPROLIX®, ELOCTATE® and SPINRAZA®. From 2008 to 2011, Dr. Brennan was director of clinical development at Tolerx, Inc., a start-up biotechnology company focusing on immunotherapy for Type 1 diabetes. Dr. Brennan serves on the board of directors of Cerevance, a clinical stage, private biopharmaceutical company advancing new medicines for brain diseases. Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and completed her post-graduate training in internal medicine, endocrinology and metabolism at the Royal College of Physicians in Ireland. Additionally, she completed her post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. The Board has concluded that Dr. Brennan possesses specific attributes that qualify her to serve as a member of our Board, including the perspective and experience she brings as our President and Chief Executive Officer, which brings operational expertise to our Board.
What is the salary of Aoife Brennan?
As the President, Chief Executive Officer és Director of Synlogic Inc, the total compensation of Aoife Brennan at Synlogic Inc is $1,793,870. There are no executives at Synlogic Inc getting paid more.
How old is Aoife Brennan?
Aoife Brennan is 44, he's been the President, Chief Executive Officer és Director of Synlogic Inc since 2018. There are 12 older and 3 younger executives at Synlogic Inc. The oldest executive at Synlogic Inc is Richard Shea, 68, who is the Independent Director.
What's Aoife Brennan's mailing address?
Aoife's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.
Insiders trading at Synlogic Inc
Over the last 7 years, insiders at Synlogic Inc have traded over $330,991 worth of Synlogic Inc stock and bought 17,000 units worth $31,190 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Synlogic Inc executives and independent directors trade stock every 132 days with the average trade being worth of $7,257. The most recent stock trade was executed by Mary Beth Dooley on 2 April 2024, trading 188 units of SYBX stock currently worth $325.
What does Synlogic Inc do?
at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre
What does Synlogic Inc's logo look like?
Complete history of Aoife Brennan stock trades at FibroGen Inc és Synlogic Inc
Synlogic Inc executives and stock owners
Synlogic Inc executives and other stock owners filed with the SEC include:
-
Aoife Brennan,
President, Chief Executive Officer, Director -
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc,
Pres, CEO & Director -
Antoine Awad,
Chief Operating Officer -
Richard Riese,
Chief Medical Officer -
Patricia Hurter,
Independent Director -
Peter Barrett,
Independent Chairman of the Board -
Richard Shea,
Independent Director -
Edward Mathers,
Independent Director -
Nick Leschly,
Independent Director -
Chau Khuong,
Independent Director -
Michael Burgess,
Independent Director -
Michael Slater,
Head of Regulatory Affairs -
David Hava,
Chief Scientific Officer -
Gregg Beloff,
Interim Chief Financial Officer -
Ajay Munshi,
VP of Corp. Devel. -
Adam Thomas,
Chief People Officer & Sec. -
Michael Jensen,
Chief Financial Officer -
Dr. Timothy K. Lu M.D., Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Michael Conlon,
VP of Corp. Devel. -
Brendan St. Amant,
Head of Legal -
Daniel Rosan,
Sr. VP & Head of Investor Relations -
Dr. Elizabeth Wolffe,
Head of Investor Relations & Corp. Communications -
Dr. David L. Hava Ph.D.,
Chief Scientific Officer -
Gregg D. Beloff J.D., M.B.A.,
Interim Chief Financial Officer -
Dr. James J. Collins Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. Timothy K. Lu,
Co-Founder -
Todd Shegog,
See Remarks -
Scott D Sandell,
10% owner -
Ravi Viswanathan,
10% owner -
David M Mott,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Forest Baskett,
10% owner -
Michael Powell,
Director -
Peter W. Sonsini,
10% owner -
Patrick J Kerins,
10% owner -
M James Barrett,
10% owner -
Peter J Barris,
10% owner -
Enterprise Associates 14, L...,
-
Advisors Llc Orbi Med Capit...,
-
Jose Carlos Gutierrez Ramos,
See Remarks -
Paul Francis Miller,
Chief Scientific Officer -
Scott Eric Plevy,
Chief Scientific Officer -
Michael Vangsted Jensen,
Chief Financial Officer -
Antoine Awad,
Chief Operating Officer -
Michael Thomas Heffernan,
-
Lisa Kelly Croswell,
-
James P Flynn,
-
Mary Beth Dooley,
Head of Finance